These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33406479)

  • 1. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
    Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33406479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
    Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33411674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.
    Traub J; Häusser-Kinzel S; Weber MS
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
    Kim SH; Hyun JW; Kim HJ
    Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
    Redenbaugh V; Flanagan EP
    Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
    Cotchett KR; Dittel BN; Obeidat AZ
    Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
    Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
    Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
    Rigal J; Ciron J; Lépine Z; Biotti D
    Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.